ANN ARBOR, Mich., August 4, 2008 — Lycera Corporation today announced that it entered into a licensing agreement with a leading specialty pharmaceutical company in the United States to develop and commercialize a series of novel small molecules for the topical treatment of human dermal conditions, including mild to moderate psoriasis. According to the National Institutes of Health, approximately 7.5 million Americans have psoriasis, a chronic skin disease characterized by itching and red, scaly patches of skin.
According to IMS Health, sales of psoriasis drugs in the United States were nearly $1 billion in 2006. Topical drugs for psoriasis include steroids, vitamin D analogues, retinoids, and coal tar. For many patients, such therapies are either ineffective, or lead to unacceptable side effects. Unlike most drugs for psoriasis, the Lycera compounds selectively block the proliferation of psoriatic skin cells. In preclinical models of psoriasis, several Lycera molecules demonstrated outstanding efficacy without altering normal skin cells and tissue. These data, published earlier this year in the Journal of Pharmacology and Experimental Therapeutics, suggest the potential for development of new psoriasis drugs with leading efficacy and safety.
The license provides for the worldwide right to practice various patents, patent applications and related technology covering the compounds and methods of using them topically to treat psoriasis and other skin diseases. Under the terms of the agreement, Lycera will receive an upfront licensing fee, milestone payments that are based upon the achievement of various development and sales milestones, and a royalty stream based on sales milestones.
Gary Glick, Ph.D., Founder of Lycera said “This license is a very important early milestone for the company and validation of our technology. These compounds will enter a very competitive space in the pharmaceutical industry. Our partner clearly recognizes the novelty of our approach. We are excited to be working with the leader in this area and look forward to seeing the results of our collaboration.”
About Lycera Corporation
Lycera Corp. is focused on the discovery and development of small-molecule immunomodulators for the treatment of immunologic diseases, including psoriasis, rheumatoid arthritis, lupus erythematosis, inflammatory bowel disease and transplant rejection. Originally founded by Dr. Gary Glick as a spin-out of the University of Michigan, Lycera is developing drug candidates that target two novel therapeutic pathways and have the potential for first-in-class oral efficacy without the adverse effects of current standard-of-care antiproliferative and immunosuppressive agents. Visit www.lycera.com for more information.